Lukas Käsmann1, Louisa Bolm1, Steven E Schild2, Stefan Janssen1,3, Dirk Rades4. 1. Department of Radiation Oncology, University of Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany. 2. Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, USA. 3. Medical Practice for Radiotherapy and Radiation Oncology, Hanover, Germany. 4. Department of Radiation Oncology, University of Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany. rades.dirk@gmx.net.
Abstract
INTRODUCTION: Patients with limited disease small-cell lung cancer (SCLC) receive radiochemotherapy followed by prophylactic cranial irradiation. The prognosis of these patients remains poor with a median survival of 16-24 months. Systemic inflammation was suggested as an important prognostic factor for outcomes. This study investigated the impact of systemic inflammation measured with neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) at first diagnosis in patients with limited disease SCLC for outcomes. METHODS: Data of 65 patients receiving radiochemotherapy for limited disease SCLC were analyzed. NLR and PLR were obtained from blood sample at first diagnosis of SCLC and 12 characteristics including gender, age, ECOG, T-category, N-category, pack years, smoking during radiotherapy, respiratory insufficiency, hemoglobin levels during radiotherapy, radiation dose (<56 vs. ≥56 Gy), concurrent radiochemotherapy, and prophylactic cranial irradiation (PCI) were evaluated for local control, metastasis-free survival, and overall survival. RESULTS: Survival rates at 1, 2, and 3 years were 71, 45, and 28%, respectively. Median survival time was 20 months. Independent factors for improved survival were NLR < 4 (p = 0.03), ECOG 0-1 (p = 0.002), and PCI (p = 0.015). Lower T-category was an independent positive factor of local control (p = 0.035). Improved metastasis-free survival was associated with NLR < 4 (p = 0.011), ECOG 0-1 (p = 0.002), N-category 0-1 (p = 0.048), non-smoking during radiotherapy (p = 0.009), and PCI (p = 0.006). CONCLUSION: NLR was found to be an independent prognostic factor for overall survival. The evaluation of NLR can help identify patients with poor prognosis and appears a useful prognostic marker in clinical practice. A prospective analysis is warranted to confirm these findings.
INTRODUCTION:Patients with limited disease small-cell lung cancer (SCLC) receive radiochemotherapy followed by prophylactic cranial irradiation. The prognosis of these patients remains poor with a median survival of 16-24 months. Systemic inflammation was suggested as an important prognostic factor for outcomes. This study investigated the impact of systemic inflammation measured with neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) at first diagnosis in patients with limited disease SCLC for outcomes. METHODS: Data of 65 patients receiving radiochemotherapy for limited disease SCLC were analyzed. NLR and PLR were obtained from blood sample at first diagnosis of SCLC and 12 characteristics including gender, age, ECOG, T-category, N-category, pack years, smoking during radiotherapy, respiratory insufficiency, hemoglobin levels during radiotherapy, radiation dose (<56 vs. ≥56 Gy), concurrent radiochemotherapy, and prophylactic cranial irradiation (PCI) were evaluated for local control, metastasis-free survival, and overall survival. RESULTS: Survival rates at 1, 2, and 3 years were 71, 45, and 28%, respectively. Median survival time was 20 months. Independent factors for improved survival were NLR < 4 (p = 0.03), ECOG 0-1 (p = 0.002), and PCI (p = 0.015). Lower T-category was an independent positive factor of local control (p = 0.035). Improved metastasis-free survival was associated with NLR < 4 (p = 0.011), ECOG 0-1 (p = 0.002), N-category 0-1 (p = 0.048), non-smoking during radiotherapy (p = 0.009), and PCI (p = 0.006). CONCLUSION: NLR was found to be an independent prognostic factor for overall survival. The evaluation of NLR can help identify patients with poor prognosis and appears a useful prognostic marker in clinical practice. A prospective analysis is warranted to confirm these findings.
Authors: Eric Vallières; Frances A Shepherd; John Crowley; Paul Van Houtte; Pieter E Postmus; Desmond Carney; Kari Chansky; Zeba Shaikh; Peter Goldstraw Journal: J Thorac Oncol Date: 2009-09 Impact factor: 15.609
Authors: M H Kang; S-I Go; H-N Song; A Lee; S-H Kim; J-H Kang; B-K Jeong; K M Kang; H Ling; G-W Lee Journal: Br J Cancer Date: 2014-06-12 Impact factor: 7.640
Authors: Ryoko Suzuki; Steven H Lin; Xiong Wei; Pamela K Allen; James W Welsh; Lauren A Byers; Ritsuko Komaki Journal: Radiother Oncol Date: 2018-02-02 Impact factor: 6.280
Authors: Michele Moschetta; Mario Uccello; Benjamin Kasenda; Gabriel Mak; Anissa McClelland; Stergios Boussios; Martin Forster; Hendrik-Tobias Arkenau Journal: Biomed Res Int Date: 2017-11-28 Impact factor: 3.411
Authors: Alexis Vallard; Max-Adrien Garcia; Peng Diao; Sophie Espenel; Guy de Laroche; Jean-Baptiste Guy; Majed Ben Mrad; Chloé Rancoule; David Kaczmarek; Thierry Muron; Gregoire Pigné; Jack Porcheron; Michel Peoc'h; Jean-Marc Phelip; Julien Langrand-Escure; Nicolas Magné Journal: Oncotarget Date: 2018-04-27
Authors: Denise Bernhardt; Sophie Aufderstrasse; Laila König; Sebastian Adeberg; Farastuk Bozorgmehr; Petros Christopoulos; Rami A El Shafie; Juliane Hörner-Rieber; Jutta Kappes; Michael Thomas; Felix Herth; Martin Steins; Jürgen Debus; Stefan Rieken Journal: Cancer Manag Res Date: 2018-11-30 Impact factor: 3.989